Moneycontrol PRO

business

Price erosion won't impact generic cos in US: Dishman Pharma

Pharmaceutical stocks have been under the US FDA cloud. Will 2017 fare better? CNBC-TV18's Latha Venkatesh & Sonia Shenoy asks Arpit Vyas, MD of Dishman Pharmaceuticals & Chemicals, Surajit Pal of Prabhudas Lilladher and Vishal Manchanda of Nirmal Bang Institutional Equities.

first published: Dec 29, 2016 11:11 am

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347